DDIT3 and diffuse large B-cell lymphoma: Recently, the ACD4C was identified as a prognostic marker in indolent lymphomas.21, 22 Even in DLBCL, ACD4C was suggested as a prognostic marker in patients with R-CHOP.23 To further investigate the relationships of the host immunity at diagnosis with survival of DLBCL patients after R-CHOP and with other prognostic factors of DLBCL are crucial factors for improving the standard therapy in DLBCL.